Stock Track | HENGRUI PHARMA Soars 7.27% Intraday on Clinical Trial Approval for HRS9531 Injection

Stock Track03-27

HENGRUI PHARMA's stock surged 7.27% during midday trade on Friday, reflecting strong investor sentiment.

The sharp increase followed news that the company's unit, Fujian Shengdi Pharmaceutical, obtained approval from China's National Medical Products Administration for clinical trials of HRS9531 injection. The drug is intended to reduce the risk of major adverse cardiovascular events in patients with atherosclerotic cardiovascular disease.

This regulatory milestone represents a positive step forward in HENGRUI PHARMA's research and development pipeline, potentially contributing to future growth prospects in the cardiovascular therapeutic area.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120817692?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 13:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120817692","market":"hk","top_or_hot":-1,"title":"Stock Track | HENGRUI PHARMA Soars 7.27% Intraday on Clinical Trial Approval for HRS9531 Injection","media":"Stock Track","content":"<p>HENGRUI PHARMA's stock surged 7.27% during midday trade on Friday, reflecting strong investor sentiment.</p><p>The sharp increase followed news that the company's unit, Fujian Shengdi Pharmaceutical, obtained approval from China's National Medical Products Administration for clinical trials of HRS9531 injection. The drug is intended to reduce the risk of major adverse cardiovascular events in patients with atherosclerotic cardiovascular disease.</p><p>This regulatory milestone represents a positive step forward in HENGRUI PHARMA's research and development pipeline, potentially contributing to future growth prospects in the cardiovascular therapeutic area.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | HENGRUI PHARMA Soars 7.27% Intraday on Clinical Trial Approval for HRS9531 Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | HENGRUI PHARMA Soars 7.27% Intraday on Clinical Trial Approval for HRS9531 Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-27 13:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENGRUI PHARMA's stock surged 7.27% during midday trade on Friday, reflecting strong investor sentiment.</p><p>The sharp increase followed news that the company's unit, Fujian Shengdi Pharmaceutical, obtained approval from China's National Medical Products Administration for clinical trials of HRS9531 injection. The drug is intended to reduce the risk of major adverse cardiovascular events in patients with atherosclerotic cardiovascular disease.</p><p>This regulatory milestone represents a positive step forward in HENGRUI PHARMA's research and development pipeline, potentially contributing to future growth prospects in the cardiovascular therapeutic area.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1120817692","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120817692","pubTimestamp":1774589901,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"HENGRUI PHARMA's stock surged 7.27% during midday trade on Friday, reflecting strong investor sentiment.The sharp increase followed news that the company's unit, Fujian Shengdi Pharmaceutical,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"个股赛道|恒瑞医药盘中暴涨7.27%HRS9531注射液获批临床试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"HENGRUI PHARMA's stock surged 7.27% during midday trade on Friday, reflecting strong investor sentiment.The sharp increase followed news that the company's unit, Fujian Shengdi Pharmaceutical, obtained approval from China's National Medical Products Administration for clinical trials of HRS9531 injection. The drug is intended to reduce the risk of major adverse cardiovascular events in patients with atherosclerotic cardiovascular disease.This regulatory milestone represents a positive step forward in HENGRUI PHARMA's research and development pipeline, potentially contributing to future growth prospects in the cardiovascular therapeutic area.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120817692","isCrawlerRequest":true}